Clinical implications of loss of interruption variants for diagnosis, genetic counselling, and clinical trials in Huntington's disease

Age of onset in Huntington disease (HD) is influenced by cis- acting genetic variants, particularly the loss of interrupting codons in the HTT CAG and CCG repeats (CAG-CCG LOI variant). The CAG-CCG LOI variant is not detectable by current diagnostic assays, leading to underestimation of CAG repeat length, misdiagnosis, and inaccurate prediction of risk of symptom onset in the reduced penetrance range. In clinical trials, unidentified CAG-CCG LOI variants may affect interpretation of results, particularly for small trials. Accurate ascertainment and reporting of the CAG-CCG LOI genotype therefore has important implications for HD diagnosis, genetic counselling, and clinical trial design.

Authors

Institutions

Publication Details

Journal
Journal of Huntington s Disease
Published
2026-05-27
DOI
https://doi.org/10.1177/18796397261443135
Primary Topic
Genetic Neurodegenerative Diseases
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Clinical implications of loss of interruption variants for diagnosis, genetic counselling, and clinical trials in Huntington's disease

Hailey Findlay Black, Kyla Javier, Chris Kay, Jessica Levesley et al.
Journal of Huntington s Disease
Genetic Neurodegenerative Diseases
article

Clinical implications of loss of interruption variants for diagnosis, genetic counselling, and clinical trials in Huntington's disease

Hailey Findlay Black, Kyla Javier, Chris Kay, Jessica Levesley, Michael R Hayden, Stephanie Bortnick
article en

Abstract

Age of onset in Huntington disease (HD) is influenced by cis- acting genetic variants, particularly the loss of interrupting codons in the HTT CAG and CCG repeats (CAG-CCG LOI variant). The CAG-CCG LOI variant is not detectable by current diagnostic assays, leading to underestimation of CAG repeat length, misdiagnosis, and inaccurate prediction of risk of symptom onset in the reduced penetrance range. In clinical trials, unidentified CAG-CCG LOI variants may affect interpretation of results, particularly for small trials. Accurate ascertainment and reporting of the CAG-CCG LOI genotype therefore has important implications for HD diagnosis, genetic counselling, and clinical trial design.

Journal of Huntington s Disease
University of British Columbia (CA)
BC Children's Hospital, Canadian Institutes of Health Research
Openalex Percentile: Top 8%
Genetic Neurodegenerative Diseases
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.